CytomX Therapeutics beats earnings and revenue estimates, stock has declined 40.3% this year

From Nasdaq: 2025-03-06 17:35:03

CytomX Therapeutics (CTMX) reported earnings of $0.22 per share, surpassing expectations and representing a 210% earnings surprise. Revenues for the quarter were $38.09 million, beating estimates by 89.28%. The stock has declined 40.3% this year. Analysts are awaiting management’s commentary for future guidance. Voyager Therapeutics (VYGR) is expected to release earnings on March 11, with an anticipated loss of $0.35 per share and revenues of $20.13 million.

Investors are eagerly awaiting CytomX Therapeutics’ earnings outlook to determine future stock performance. The company’s recent earnings beat and revenue surpass have impacted its stock movement. Analysts are monitoring estimate revisions closely to gauge potential stock movement. Industry outlook is crucial for stock performance, with Medical – Biomedical and Genetics currently ranked in the top 27% of Zacks industries.

For those considering investing in CytomX Therapeutics, Zacks Investment Research offers valuable insights and analysis. With a track record of providing independent research and tools, Zacks Investment Research highlights the top 7 stocks to buy for the next 30 days. Investors can access the latest recommendations and stock analysis reports for both CTMX and VYGR on Zacks’ platform.



Read more at Nasdaq: CytomX Therapeutics (CTMX) Tops Q4 Earnings and Revenue Estimates